# US 2026/0102388 A1 · Compound slow-release implant of naltrexone and risperidone, preparation method therefor, and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0102388 A1
- Document ID: US20260102388A1
- Status: Published application
- Kind: A1
- Application number: 19/115,631
- Filed: 2023-09-27
- Published: 2026-04-16
- Earliest claimed: 2022-09-28
- Assignees: Shenzhen ScienCare Pharmaceutical Co., Ltd.
- Applicants: Shenzhen ScienCare Pharmaceutical Co., Ltd.
- Inventors: Xieguo YAN; Fuqiao YAN; Yamin HUANG; Shugui YIN; Wei QU; Tao ZHANG; Xingjian DENG; Xinmin QIU
- Web page: https://patentgrep.com/patent/US20260102388A1

## CPC

- A61K 31/485: Morphinan derivatives, e.g. morphine, codeine
- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 9/1647: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K 9/1694: {resulting in granules or microspheres of the matrix type containing more than 5% of excipient}
- A61K 9/2009: {Inorganic compounds}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/204: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K 9/2077: {Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets}
- A61K 9/2095: {Tabletting processes}
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61P 25/30: for treating abuse or dependence
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed is a compound sustained release implant of naltrexone and risperidone, and a preparation method and application thereof, which belong to the technical field of implant preparation. The naltrexone compound sustained-release implant includes naltrexone, risperidone, a degradable material A, a degradable material B, an additive and a lubricant. By controlling a mass ratio of naltrexone to risperidone to be (20-30):1, a weight-average molecular weight of the degradable material A to be 10-15 W, and a weight-average molecular weight of the degradable material B in risperidone microspheres to be 2 W-4 W, the compound sustained release implant of naltrexone and risperidone can not only effectively inhibit amphetamine type drug relapse and reduce side effects of risperidone, but also realize the synchronous release of naltrexone and risperidone.

## Claims

### Claim 1

A sustained-release implant, comprising naltrexone, risperidone, a degradable material A, a degradable material B, an additive and a lubricant, wherein the naltrexone and the risperidone have a mass ratio of 20-30:1.

### Claim 2 (depends on 1)

The sustained-release implant according to claim 1, wherein:
the naltrexone and the degradable material A have a mass ratio of (10-40):(60-90);
the risperidone and the degradable material B have a mass ratio of (40-60):(40-60);
the degradable material A has a weight-average molecular weight of 10 W-15 W; and
the degradable material B has a weight-average molecular weight of 2 W-4 W.

### Claim 3 (depends on 1)

The sustained-release implant according to claim 1, wherein:
the degradable material A is selected from the group consisting of PEG-PLGA, PLA, PLGA and PCL;
the degradable material B is selected from the group consisting of PLA, PLGA and PCL,
the additive is selected from the group consisting of sodium chloride, sodium bicarbonate, disodium hydrogencarbonate, potassium chloride and phosphate; and
the lubricant is selected from the group consisting of magnesium stearate, stearic acid and sodium stearyl fumarate.

### Claim 4 (depends on 1)

A method of preparing the sustained-release implant of claim 1, comprising the steps of:
(1) preparing naltrexone microspheres by:
(1.1) dissolving an additive in water, to obtain an aqueous phase W1;
(1.2) dissolving naltrexone and 30%-60% of a degradable material A in an organic solvent A, to obtain an oil phase O1;
(1.3) adding the aqueous phase W1 into the oil phase O1, ultrasonically emulsifying to form W1/O1 primary emulsion;
(1.4) dissolving the remaining degradable material A in the organic solvent A, to obtain an oil phase O2;
(1.5) adding the W1/O1 primary emulsion into the oil phase O2, ultrasonically emulsifying to form W1/O1/O2 multiple emulsion;
(1.6) preparing an aqueous solution of polyvinyl alcohol (PVA) to obtain an aqueous phase W2; and
(1.7) dispersing the W1/O1/O2 multiple emulsion to the aqueous phase W2, stirring until the organic solvent A is volatilized, filtering and collecting resulting microspheres, washing and drying to obtain the naltrexone microspheres;
(2) preparing risperidone microspheres by:
(2.1) dissolving risperidone and 50%-80% of a degradable material B in the organic solvent A, to obtain an oil phase O;
(2.2) preparing an aqueous solution of PVA to obtain an aqueous phase W; and
(2.3) adding the oil phase O into the aqueous phase W, stirring until the organic solvent A is volatilized, filtering and collecting resulting microspheres, washing and drying to obtain the risperidone microspheres;
(3) preparing poly lactic acid (PLA) blank particles by:
dissolving the remaining degradable material B in an organic solvent B to obtain a solution; and
adding the solution dropwise into a phosphate buffer to obtain polymer blank particles;
(4) blending the naltrexone microspheres and the risperidone microspheres, adding and blending with the polymer blank particles and a lubricant, and then pressing into cylindrical tablets; and
(5) sterilizing the cylindrical tablets by irradiation to obtain the sustained-release implant.

### Claim 5 (depends on 4)

The method of claim 4, wherein in step (1.1), the additive in the aqueous phase W1 has a concentration of 0-30 mg/mL.

### Claim 6 (depends on 4)

The method of claim 4, wherein in steps (1.2), (1.4), (1.7), (2.1) and (2.3), the organic solvent A is selected from dichloromethane or/and ethyl acetate; preferably dichloromethane.

### Claim 7 (depends on 4)

The method of claim 4, wherein:
in step (1.2), the naltrexone in the oil phase O1 has a concentration of 100-300 mg/mL;
in step (1.2), the degradable material A in the oil phase O1 has a concentration of 100-300 mg/mL; and
in step (1.4), the degradable material A in the oil phase O2 has a concentration of 200-400 mg/mL.

### Claim 8 (depends on 4)

The method of claim 4, wherein:
in steps (1.6) and (2.2), the PVA in the aqueous phase W2 has a mass fraction of 0.1-1.2%; the aqueous phase W2 further comprises sodium chloride, and the sodium chloride has a mass fraction of 0-10%;
in step (2.1), the risperidone in the oil phase O has a concentration of 50-300 mg/mL; the degradable material B in the oil phase O has a concentration of 100-300 mg/mL; and
in step (3), the degradable material B in the solution has a mass fraction of 10-25%.

### Claim 9 (depends on 4)

The method of claim 4, wherein in step (4), the polymer blank particles accounts for 5-10% w/w of the total; the lubricant accounts for 0-0.05% w/w of the total.

### Claim 10 (depends on 1)

A method for treating or relieving amphetamine-type drug addiction in a subject in need thereof, comprising administering to the subject the sustained-release implant of claim 1.

### Claim 11 (depends on 5)

The method or claim 5, wherein in step (1.1), the additive in the aqueous phase W1 has a concentration of 10-25 mg/mL.

### Claim 12 (depends on 7)

The method of claim 7, wherein:
in step (1.2), the naltrexone in the oil phase O1 has a concentration of 150-250 mg/mL;
in step (1.2), the degradable material A in the oil phase O1 has a concentration of 100-200 mg/mL; and
in step (1.4), the degradable material A in the oil phase 02 has a concentration of 250-350 mg/mL.

### Claim 13 (depends on 8)

The method of claim 8, wherein:
in step (2.1), the risperidone in the oil phase O has a concentration of 100-200 mg/mL; the degradable material B in the oil phase O has a concentration of 100-200 mg/mL; and
in step (3), the degradable material B in the solution has a mass fraction of 10%-15%.
